发布求助
文献互助 智能选刊 最新文献

Current interventional cardiology reports最新文献

筛选
英文 中文
Local Drug Delivery During Percutaneous Coronary Intervention. 经皮冠状动脉介入治疗中的局部给药。
Current interventional cardiology reports Pub Date : 2000-11-01
Bailey
{"title":"Local Drug Delivery During Percutaneous Coronary Intervention.","authors":"Bailey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Local delivery of therapeutic agents offers promise as adjuncts during percutaneous interventions. The potential advantages of local delivery include direct delivery to the lesion site, lower doses of the agent resulting in lower costs and/or greater efficiency, and the potential for increased potency. Early trials focused primarily on the use of anti-thrombotic therapy using agents such as urokinase, heparin, and the heparinoids. These therapies, limited by an inadequate knowledge of the pharmacodynamics of the agents, had disappointing outcomes. Recent trials have focused on the use of later generation delivery devices that have improved delivery kinetics as well as agents that have improved resonance within the artery wall. It is anticipated that these new approaches will improve the clinical outcomes of local drug delivery during percutaneous interventions.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21920559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene Therapy for Coronary Restenosis: A Promising Strategy for the New Millennium? 基因治疗冠状动脉再狭窄:新千年的一个有希望的策略?
Current interventional cardiology reports Pub Date : 2000-11-01
Varenne, Sinnaeve
{"title":"Gene Therapy for Coronary Restenosis: A Promising Strategy for the New Millennium?","authors":"Varenne,&nbsp;Sinnaeve","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Gene therapy is an attractive alternative for reducing restenosis after percutaneous coronary interventions. Several approaches, using genes encoding antiproliferative, antimigratory, cytostatic, or cytotoxic proteins have been successfully tested in relevant animal models. Antiproliferative, gene-based strategies also appear to be good candidates for the highly proliferative lesion responsible for in-stent restenosis. However, several key issues, including vector safety and delivery mechanisms, still have to be resolved before percutaneous gene therapy can be widely applied in the clinic. The amount of experimental research in this field indicates a medical evolution that can (and should) not be ignored by cardiologists.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21921279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Thrombolytic Agents: Does Direct Angioplasty Still Have a Role? 新的溶栓药物:直接血管成形术是否仍有作用?
Current interventional cardiology reports Pub Date : 2000-08-01
Llevadot, Giugliano
{"title":"New Thrombolytic Agents: Does Direct Angioplasty Still Have a Role?","authors":"Llevadot,&nbsp;Giugliano","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The optimal method of reperfusion for patients with ST-segment elevation acute myocardial infarction has been a point of controversy over the last two decades. Tenecteplase and reteplase are comparable to accelerated-dose alteplase but more convenient because they can be delivered as a bolus. Combination regimens represent a further advance in reperfusion therapy; planned and ongoing studies will evaluate the clinical efficacy and safety of combination therapy. Promising early results of primary coronary intervention with glycoprotein IIb/IIIa receptor inhibition have been reported, and this strategy may emerge as a mainstay of therapy at hospitals with on-site interventional facilities. A possible future approach that could be universally applied consists of combination therapy and adjunctive/rescue percutaneous intervention in selected patients.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of Efficacy: Safety Concerns and Early Results. 疗效机制:安全性问题和早期结果。
Current interventional cardiology reports Pub Date : 2000-08-01
Bashir, Vale, Isner, Losordo
{"title":"Mechanisms of Efficacy: Safety Concerns and Early Results.","authors":"Bashir,&nbsp;Vale,&nbsp;Isner,&nbsp;Losordo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Coronary and peripheral atherosclerotic diseases affect more than 15 million patients in the United States alone. Over the last three decades significant progress has been made in the management of these patients using medical, surgical, and percutaneous therapies. However, there remains a significant population of patients who are not optimal candidates for surgical or percutaneous revascularization. These patients continue to suffer from the debilitating symptoms of their disease and remain at risk for myocardial events, limb loss, or death. It was this clinical need, coupled with the advances in the understanding of angiogenesis, that has led to efforts to develop angiogenic therapies for patients with peripheral and myocardial ischemia. In general, these conditions are characterized by local hypovascularity, and the approach to treatment is focused on stimulating neovascularization, ie, therapeutic angiogenesis.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on Abciximab Readministration During Percutaneous Coronary Interventions. 经皮冠状动脉介入治疗期间阿昔单抗再用药的最新进展。
Current interventional cardiology reports Pub Date : 2000-08-01
Madan, Tcheng
{"title":"Update on Abciximab Readministration During Percutaneous Coronary Interventions.","authors":"Madan,&nbsp;Tcheng","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Abciximab is a monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor and is increasingly used as an adjunct to percutaneous coronary intervention. Because some patients will return for additional revascularization procedures, it is anticipated that abciximab retreatment may be necessary. There exists at least the theoretic potential for immunologic reactions and diminished efficacy upon re-exposure to abciximab. The limited data available regarding abciximab retreatment suggests that readministration is as safe and effective as first-time treatment, provided certain precautions are taken. This review summarizes the available clinical data and provides suggestions for safe abciximab readministration.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of CardioSEAL and Starflex Devices in Atrial Defect Occlusion. CardioSEAL和Starflex装置在房缺损封堵中的作用。
Current interventional cardiology reports Pub Date : 2000-08-01
Pedra, McLaughlin, Benson
{"title":"The Role of CardioSEAL and Starflex Devices in Atrial Defect Occlusion.","authors":"Pedra,&nbsp;McLaughlin,&nbsp;Benson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The CardioSEAL and Starflex implants (Nitinol Medical Technologies, Boston, MA) are self-expanding, double-umbrella septal occluders designed to close small to moderate secundum atrial septal defects (ASDs), the latter having a self-centering mechanism. Overall, successful clinical defect occlusion occurs in more than 90% of patients following implantation. In this article, we discuss the development, design issues, technique of implantation, and clinical results pertinent to these new devices.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21921275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. 局部血管周围和心包输送治疗性血管生成。
Current interventional cardiology reports Pub Date : 2000-08-01
Laham, Post, Sellke, Simons
{"title":"Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery.","authors":"Laham,&nbsp;Post,&nbsp;Sellke,&nbsp;Simons","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Therapeutic angiogenesis is a potential new treatment strategy that promises to grow new blood vessels to the ischemic myocardium in patients with ischemic heart disease. Despite its investigation in more than 550 patients with ischemic heart disease, the concept of clinical therapeutic angiogenesis remains a theoretic one with more questions than answers. This is due in part to a poor understanding of the fundamental mechanisms of adult collateralization and growth factor-induced angiogenesis, a poor understanding of the relative importance of large epicardial feeding collaterals versus intramyocardial neovascularization, and limited data concerning the best angiogenic cytokine, the best delivery modality, and the need for sustained exposure to that cytokine. This article discusses the available data on local perivascular delivery and pericardial delivery as they pertain to therapeutic angiogenesis. These delivery strategies have several characteristics that may make them ideal as adjuncts for coronary artery bypass surgery (local perivascular delivery) or in noninstrumented pericardium (pericardial delivery). They also have the theoretic advantage of affecting epicardial vessels and potentially promoting epicardial feeding collaterals.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contrast Agents for Cardiac Angiography: Osmolality and Contrast Complications. 心脏血管造影剂:渗透压和造影剂并发症。
Current interventional cardiology reports Pub Date : 2000-08-01
R A Krasuski, M H Sketch, J K Harrison
{"title":"Contrast Agents for Cardiac Angiography: Osmolality and Contrast Complications.","authors":"R A Krasuski,&nbsp;M H Sketch,&nbsp;J K Harrison","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Radiographic contrast agents have undergone a tremendous evolution over the past several decades. The creation of contrast agents with greater iodine carrying capacity and lower osmolality has improved imaging quality and reduced complications, including nausea, vomiting, congestive heart failure, and cardiac rhythm abnormalities. Whether differences exist among agents in terms of thrombotic complications remains controversial. Several characteristics including potential complications, toxicity, and cost must factor into the decision to use a particular contrast agent in cardiac procedures.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging Angiogenesis with Three-Dimensional Microscopic Computed Tomography. 三维显微计算机断层成像血管生成。
Current interventional cardiology reports Pub Date : 2000-08-01
B Kantor, E L Ritman, D R Holmes, R S Schwartz
{"title":"Imaging Angiogenesis with Three-Dimensional Microscopic Computed Tomography.","authors":"B Kantor,&nbsp;E L Ritman,&nbsp;D R Holmes,&nbsp;R S Schwartz","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An increasing number of patients with advanced coronary artery disease remain symptomatic, despite maximal interventional or medical treatment. A high demand exists for alternative anti-anginal therapies and ways to improve survival. One of the most intriguing new approaches to increase blood flow to ischemic myocardium is therapeutic angiogenesis, the induction of new vessel growth. Current methods involve local angiogenic growth factor administration, transfection of genes expressing angiogenic proteins, or direct myocardial revascularization. These new therapeutics are undergoing intensive basic and clinical investigation.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. 血管内皮生长因子治疗血管生成的临床前和临床结果综述。
Current interventional cardiology reports Pub Date : 2000-08-01
Henry, Abraham
{"title":"Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis.","authors":"Henry,&nbsp;Abraham","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Therapeutic angiogenesis is a novel approach to the treatment of coronary and peripheral vascular disease not amenable to standard revascularization techniques. Vascular endothelial growth factors (VEGFs) are a family of angiogenic proteins specific for endothelial cells and essential in the process of angiogenesis. Successful therapeutic angiogenesis has been demonstrated using VEGF in preclinical models. Based on initial clinical results, VEGF is a promising approach to ischemic vascular disease, but long-term safety and efficacy remain unproven.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21922065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信